Findings

What do systematic reviews say?

68 questions · 69 findings · 5 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 21 · 30.4%GRADE not reported 0 · 0%Very low 29 · 42%Low 12 · 17.4%Moderate 7 · 10.1%High 0 · 0%

Long‐term red cell transfusion vs hydroxyurea and phlebotomy

Serious adverse events as a result of sickle cell‐related complications · individuals with sickle cell disease who have had a stroke who have had long‐term red cell transfusions to prevent another stroke

It is very uncertain whether long‐term red cell transfusion changes serious adverse events as a result of sickle cell‐related… compared with hydroxyurea and phlebotomy (very low certainty).

1 finding from 1 review

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
RR 0.33 [0.04, 3.08]
1 study · 133 participants
Very low

Long‐term red cell transfusion vs hydroxyurea and phlebotomy

Measures of neurological impairment ‐ not reported · individuals with sickle cell disease who have had a stroke who have had long‐term red cell transfusions to prevent another stroke

The review found no eligible studies for this question.

1 finding from 1 review

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Long‐term red cell transfusion vs hydroxyurea and phlebotomy

Quality of life ‐ not reported · individuals with sickle cell disease who have had a stroke who have had long‐term red cell transfusions to prevent another stroke

The review found no eligible studies for this question.

1 finding from 1 review

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Frequency of transfusion · people with non‐transfusion dependent beta thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Major adverse effects ‐ Neutropenia · people with non‐transfusion dependent beta thalassaemia

It is very uncertain whether the intervention changes major adverse effects ‐ Neutropenia (very low certainty).

1 finding from 1 review

Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias 2016 · Cochrane Headline outcomes only
RR 9.93 [1.34, 73.67]
1 study · 61 participants
Very low

Intervention not reported

Major adverse effects ‐ Thrombocytopenia · people with non‐transfusion dependent beta thalassaemia

It is very uncertain whether the intervention changes major adverse effects ‐ Thrombocytopenia (very low certainty).

1 finding from 1 review

Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias 2016 · Cochrane Headline outcomes only
RR 3.68 [1.12, 12.07]
1 study · 61 participants
Very low

Intervention not reported

Quality of life · people with non‐transfusion dependent beta thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Mean Hb F at 24 weeks (g/dL) · people with non‐transfusion dependent beta thalassaemia

1 finding from 1 review

Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Low